- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07940400
Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer (ICEBERG-PC)
ICEBERG-PC: Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer: A Single-Site AmbidirectionalObservational Outcomes Cohort
Management of prostate cancer increasingly integrates conventional clinicopathologic risk factors with multiparametric magnetic resonance imaging (mpMRI), targeted and systematic biopsy, molecular imaging, and selected tissue-based genomic biomarkers. Contemporary guidelines emphasize risk-adapted shared decision-making and allow selective use of tissue-based genomic biomarkers when additional risk stratification may alter management discussions.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
The central rationale is to create a source-controlled, longitudinal prostate cancer outcomes cohort in which routine-care genomics, PSMA PET, mpMRI, MRI/ultrasound fusion biopsy, pathology, treatment, and functional outcomes can be analyzed together. The historical component will provide a background population for understanding treatment patterns and outcomes when Decipher® and/or PSMA PET were not obtained. It will not be treated as a formal randomized or concurrent comparator arm. This study is designed to observe that real-world clinical process without assigning testing, imaging, or treatment.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Sachin Vyas, MS,PhD
- Telefonnummer: 336-713-4098
- E-mail: Sachin.vyas@advocatehealth.org
Studiesteder
-
-
North Carolina
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Wake Forest University Health Sciences
-
Ledende efterforsker:
- Thomas Polascik, MD
-
Kontakt:
- Sachin Vyas, MS, PhD
- Telefonnummer: 336-713-4098
- E-mail: Sachin.Vyas@Advocatehealth.org
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Diagnosis of prostate cancer
Beskrivelse
Inclusion Criteria:
- Age ≥18 years.
- Diagnosis of prostate cancer documented in the institutional medical record. Prostate adenocarcinoma will constitute the principal analytic population, while other prostate cancer histology's may be retained for descriptive background analyses when clinically relevant.
- Evaluation, diagnosis, treatment, or follow-up within or beyond Advocate Health Wake Forest Baptist / Wake Forest University School of Medicine and availability of sufficient clinical information for at least one study objective.
- For the prospective component, first ascertainment after protocol activation will be conducted through routine clinical records or institutional clinical data systems.
- For the historical background component, available institutional records predating protocol activation will be used to characterize prostate cancer presentation, management, and outcomes
Exclusion Criteria:
- Insufficient clinical information to establish the relevant diagnosis, treatment, or outcome for a proposed analysis.
- Records that cannot be used under applicable institutional privacy, data-governance, or IRB requirements.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Patients been diagnosed with the prostate cancer
To determine how clinically obtained tumor genomic and transcriptomic features, phenotype, real-world treatment selection, and longitudinal oncologic outcomes |
This study involves no study specific intervention |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Prostate-Specific Membrane Antigen (PSMA) PET disease extent
Tidsramme: up to 5 years
|
Prostate-Specific Membrane Antigen (PSMA) PET disease extent among patients with clinically obtained Decipher® and PSMA PET, classified as localized versus nonlocalized disease using available molecular-imaging staging data. |
up to 5 years
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Thomas Polascik, MD, Wake Forest University Health Sciences
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IRB00157301
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .